Form 8-K Caribou Biosciences, For: Jun 02
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Citi Reiterates Buy Rating on Caribou Biosciences Inc. (CRBU)
June 3, 2024 8:10 AM EDTCiti analyst Yigal Nochomovitz reiterated a Buy rating and $30.00 price target on Caribou Biosciences Inc. (NASDAQ: CRBU)
The analyst comments "CRBUs retrospective introduction of a partial HLA-matching strategy for CB-010 (allogeneic CD19 CAR-T) seems be bearing fruit with the reported 14.4-month PFS in patients... More
Evercore ISI Downgrades Caribou Biosciences Inc. (CRBU) to In Line
June 3, 2024 6:25 AM EDTEvercore ISI analyst Liisa Bayko downgraded Caribou Biosciences Inc. (NASDAQ: CRBU) from Outperform to In Line with a price target of $3.00 (from $13.00).
The analyst comments "CRBU may have unlocked the key to allogenic CAR-T. But we are not yet convinced that it will be... More
